REALASA: Real-world effectiveness assessment of first-line 5-ASA for the treatment of Ulcerative Colitis in Sweden

被引：0
|
作者：
Christophersen, B. [1 ]
Nielsen, L. [2 ]
Landeira, M. [3 ]
Guedes, S. [4 ]
机构：
[1] Ferring Pharmaceut Inc, Med Affairs, Copenhagen, Denmark
[2] Ferring Pharmaceut Inc, Stat, Copenhagen, Denmark
[3] Ferring Pharmaceut Inc, Hlth Econ & Outcomes Res, Copenhagen, Denmark
[4] Ferring Pharmaceut Inc, Real World Evidence, Copenhagen, Denmark
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0907
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0733
引用
收藏
页码：I1423 / I1423
页数：1
相关论文
共 50 条
  • [31] REAL-WORLD EFFECTIVENESS AND SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: A MULTICENTER STUDY
    Patel, Anish
    Johnson, Amanda M.
    Berinstein, Jeffrey
    Dulaney, David
    Fenster, Marc
    Ayoub, Malek
    Huang, Katherine
    Lieto, Stephen
    Scalzo, Nicholas
    Loftus, Edward V.
    Higgins, Peter D.
    Chowla, Navreet M.
    Reddy, Nikhil
    Yarur, Andres
    Kuang, Andrew
    Shukla, Richa
    Sekhri, Shaina
    Pekow, Joel
    Beniwal-Patel, Poonam
    Cohen, Benjamin L.
    Gutierrez, Alexandra
    Colombel, Jean Frederic
    Ciorba, Matthew A.
    Bishu, Shrinivas
    Ungaro, Ryan C.
    Deepak, Parakkal
    GASTROENTEROLOGY, 2023, 164 (06) : S1136 - S1137
  • [32] Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
    Lair-Mehiri, L.
    Stefanescu, C.
    Vaysse, T.
    Laharie, D.
    Roblin, X.
    Rosa, I.
    Treton, X.
    Abitbol, V.
    Amiot, A.
    Bouguen, G.
    Dib, N.
    Fumery, M.
    Pariente, B.
    Carbonnel, F.
    Peryn-Biroulet, L.
    Simon, M.
    Viennot, S.
    Bouhnik, Y.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S478 - S479
  • [33] Real World Comparison of Effectiveness, Durability, and Safety of First-Line Advanced Therapies for Ulcerative Proctitis
    Dalal, Rahul
    Clarke, Lindsay
    Carlin, Alexander
    Cabral, Heidy
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S736 - S737
  • [34] Real-world experience of tofacitinib in Australia for treatment of ulcerative colitis
    Khoo, E.
    Lee, A.
    Lo, S. W.
    Wright, E.
    Ghaly, S.
    Makanyanga, J.
    Thin, L.
    Fang, W.
    Niewiadomski, O.
    Chung, A.
    Digby-Bell, J.
    Sparrow, M.
    Shelton, E.
    Jakobovits, S.
    Scott, D.
    Ward, M.
    Ardalan, Z. S. M.
    An, Y-K
    Begun, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 124 - 125
  • [35] Vedolizumab: First-line Biologic for Ulcerative colitis and Crohn's Disease Real-world Data shows continued stable Disease Progression
    Ruedesheim, Sabine M.
    VISCERAL MEDICINE, 2023, 39 (3-4) : 100 - 100
  • [36] Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study
    Fischer, Aren
    Mac, Stephen
    Freiman, Erica Stivelman
    Marshall, John K.
    Rand, Kim
    Ramos-Goni, Juan M.
    PHARMACOECONOMICS-OPEN, 2024, : 41 - 56
  • [37] A real-world comparison of the effectiveness and safety of vedolizumab and anti-tumor necrosis factor therapies in early treatment initiation with first-line biological therapy in ulcerative colitis: Results from EVOLVE
    Mantzaris, G.
    Bressler, B.
    Kopylov, U.
    Bassel, M.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Yarur, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 119 - 120
  • [38] Comparative Effectiveness of First-Line Infliximab and Vedolizumab in Patients with Early Ulcerative Colitis
    Hemed, A. Rozenfeld
    Cohen, N. A.
    Green, O.
    Hirsch, A.
    Thurm, T.
    Ron, Y.
    Fishman, S.
    Leibovitzh, H.
    Maharshak, N.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1476 - I1477
  • [39] Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres
    Young, David
    Rahmany, Sohail
    Taylor, Deborah
    Davis, Emma
    Colwill, Michael
    Mehta, Sonia Kalyanji
    Campbell, Roisin
    Hazel, Karl
    Sethi-Arora, Karishma
    Ritchie, Susan
    Heinson, Ashley, I
    Moyses, Helen
    Bodger, Keith
    Johnston, Emma
    Hicks, Lucy
    Dhar, Anjan
    Limdi, Jimmy
    Cooney, Rachel
    Seenan, John Paul
    Patel, Kamal
    Walsh, Alissa
    Cummings, Fraser
    DRUGS IN CONTEXT, 2025, 14
  • [40] Cost-effectiveness of mesalamine (5-aminosalicyclic acid, 5-ASA) therapy for maintenance of remission in ulcerative colitis (UC)
    Yen, Eugene F.
    Kane, Surranda V.
    Ladabaum, Uri
    GASTROENTEROLOGY, 2006, 130 (04) : A619 - A619
12345